Customer updates during COVID pandemic Click Here >

2020 Jun 9 - Knowledge Resource Series#1 T-Cell Therapy Webinar
Christopher Bunker, Ph.D.
Senior Director, Business Development, Advanced Cell Diagnostics
Watch Video:

RNAscope in situ hybridization (ISH) is the only method for specific detection of engineered CAR-T and TCR-T cell therapies in clinical trial patient biopsies. IHC is unable to differentiate engineered T cells from endogenous cells. However, RNAscope probes targeting viral untranslated regions (UTRs) common to CAR and TCR mRNAs, enable specific detection and quantification of CAR/TCR-T cells in the tumor microenvironment (TME). RNAscope UTR probes are easily multiplexed with probes to assess activation, e.g., IFNG and GZMB, as well as with T cell IHC markers, e.g. CD3, CD4, CD8 to measure T cell recruitment. These assays are used to monitor T cell therapies in post-treatment patient biopsies and in preclinical animal models of safety and efficacy.

Learning Objectives:
  • Simultaneously detect CAR/TCR-T cells with cytokines, immune cell markers and target antigens
  • Quantification of cell therapy tumor and stromal distribution and and T cell recruitment
  • Patient biopsy analysis to link cell therapy pharmacokinetics/pharmacodynamics and efficacy.
Contact Us

Complete one of the two forms below and we will get back to you.

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798



19 Barton Lane  
Abingdon Science Park
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420



Advanced Cell Diagnostics China

Building 15, No. 26 Xihuan South Road
Beijing Economic-Technological Development Area
Beijing, China, Zip code: 100176

For general information:

For general information:
For place an order:
For product support:
For career opportunities: